IOVA Earnings

IOVA reported its earnings on 2026-02-24, showcasing a revenue of 86.71M against an estimate of 75.08M, resulting in a 15.49% surprise. The EPS was -0.18, surpassing the expected -0.22 by 18.18%. The stock experienced a 30.8% price change on the earnings day and a 33.56% change over the next five days, reflecting market reactions to the results.

Following IOVA's earnings announcement on 2026-02-24, the stock price moved by 30.8% on the day of the release. Over the subsequent five days, it saw a 33.56% change. Historically, IOVA's stock price tends to shift by an average of -7.3% in the 10 days leading up to earnings and -6.74% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate IOVA's annual revenue to reach 82.76M, while the EPS is projected at -0.15. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between IOVA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IOVA's stock price typically moves by -7.3% in the 10 days before its earnings and -6.74% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.15 and revenue of 82.76M.

The earnings call reveals strong financial performance, with promising product developments, particularly in lung cancer and melanoma markets. The company shows a commitment to cost management and profitability, with expected margin improvements. While some uncertainty exists due to lack of 2026 guidance and unclear management responses, the overall sentiment is positive, driven by optimistic guidance, international approvals, and new market opportunities. The market cap suggests moderate volatility, leading to a positive stock price movement prediction over the next two weeks.